-+ 0.00%
-+ 0.00%
-+ 0.00%

Stocks in play: Cardiol Therapeutics Inc.

Barchart·07/14/2026 08:33:00
Listen to the news

Announced the publication of its Phase II MAvERIC study results in the Journal of the American Heart Association. The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment. Cardiol Therapeutics Inc. shares T.CRDL are trading unchanged at $1.50.